Skip to main content

Form 8.3 – [LEARNING TECHNOLOGIES GROUP PLC – 12 11 2024] – (CGWL)

FORM 8.3 PUBLIC OPENING POSITION DISCLOSURE/DEALING DISCLOSURE BY A PERSON WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORERule 8.3 of the Takeover Code (the “Code”) 1.        KEY INFORMATION(a)   Full name of discloser: CANACCORD GENUITY WEALTH LIMITED (for Discretionary clients)(b)   Owner or controller of interests and short positions disclosed, if different from 1(a):        The naming of nominee or vehicle companies is insufficient. For a trust, the trustee(s), settlor and beneficiaries must be named. N/A(c)   Name of offeror/offeree in relation to whose relevant securities this form relates:        Use a separate form for each offeror/offeree LEARNING TECHNOLOGIES GROUP PLC(d)   If an exempt fund manager connected with an offeror/offeree, state this and specify identity of offeror/offeree: N/A(e)   Date...

Continue reading

Recursion and Exscientia Shareholders Approve the Proposed Combination

Update call scheduled for November 20th at 7:30 a.m. Eastern with anticipated close Salt Lake City USA, Oxford UK, Nov. 13, 2024 (GLOBE NEWSWIRE) — Recursion (Nasdaq: RXRX) and Exscientia plc (Nasdaq: EXAI) have each received overwhelming approval from their shareholders for the proposed combination between Recursion and Exscientia.  The transaction is expected to close on November 20, 2024, subject to the satisfaction or waiver of the remaining customary closing conditions. Recursion expects to host an update call after the anticipated close on November 20, 2024 at 7:30 a.m. ET /  5:30 a.m MT / 12:30 p.m. GMT. The company will broadcast the live stream from Recursion’s X (formerly Twitter), LinkedIn and YouTube accounts. Questions can be submitted via this link ahead of time or during the livestream. “The overwhelming support...

Continue reading

Smart Transportation Market to Surpass Valuation of USD 293.84 Billion by 2031 | SkyQuest Technology

Westford,USA, Nov. 13, 2024 (GLOBE NEWSWIRE) — SkyQuest projects that the Smart Transportation Market will reach a value of USD 293.84 Billion by 2031, with a CAGR of 13% during the forecast period (2024-2031). The expansion of the market is primarily attributed to the growing advancements in urban projects, the initiatives undertaken by the governments to mitigate the emissions of greenhouse gases, and the increasing demand for the inclusion of technology in traffic management systems. The majority of cities face serious challenges with low-quality, unsafe public transportation, insufficient management capabilities, diminished road safety concerns, ineffective traffic control, and parking issues (including pedestrian walkways). As a result, there will probably be a large increase in demand for smart transport systems soon. Download...

Continue reading

Clear Aligners Market to Reach Market Valuation of USD 43.4 Billion by 2031 | SkyQuest Technology

Westford,USA, Nov. 13, 2024 (GLOBE NEWSWIRE) — SkyQuest projects that the Clear Aligners Market will reach a value of USD 43.4 Billion by 2031, with a CAGR of 30.7% during the forecast period (2024-2031). Clear aligners are witnessing a surge in popularity owing to trends like aesthetics, convenience, comfort, projected results, and improved patient experience. Moreover, the market is propelled by the growing incidences of malocclusion, the rising acceptance of orthodontic treatment among a large adult population, and technological advancements that improve the effectiveness and precision of clear aligners. In addition, the growing demand for aesthetic treatments by a larger patient population is fueling the market growth. Download a detailed overview: https://www.skyquestt.com/sample-request/clear-aligners-market Browse in-depth...

Continue reading

Vaccines Market is Expected to Develop at a Moderate 3.70% CAGR through 2031 | SkyQuest Technology

Westford,USA, Nov. 13, 2024 (GLOBE NEWSWIRE) — SkyQuest projects that the Vaccines market will attain a value of USD 99.85 billion by 2031, with a CAGR of 3.70% over the forecast period (2024-2031). Surging prevalence of chronic diseases and increasing launch of new vaccination programs around the world are projected to bolster the demand for vaccines in the future. Rising investments in vaccine R&D and growing emphasis on preventive healthcare around the world are also projected to promote sales of vaccines over the coming years. Download a detailed overview:https://www.skyquestt.com/sample-request/vaccines-market Browse in-depth TOC on “Vaccines Market”Pages – 212 Tables – 147 Figures – 71Vaccines market Overview:Report Coverage DetailsMarket Revenue in 2023 $ 74.66 billionEstimated...

Continue reading

Dental Practice Management Software Market to Grow at USD 2.90 Billion by 2031

Westford,USA, Nov. 13, 2024 (GLOBE NEWSWIRE) — Dental Practice Management Software Market size was valued at USD 1.38 billion in 2022 and is poised to grow from USD 1.50 billion in 2023 to USD 2.90 billion by 2031, growing at a CAGR of 8.6% in the forecast period (2024-2031). The market is anticipated to grow significantly, owing to the rising dental visits, increasing focus & awareness about oral health, and the rapid technological advancement. The Health Information Technology for Economic and Clinical Health encouraged the growth while providing the use of health information technology in the United States. Moreover, the adoption of healthcare IT solutions, especially by the speciality clinics like oral practices is expected to increase insurance coverage. Hence, the above reasons are expected to result in the increased...

Continue reading

Entero Therapeutics Announces Proposed Reverse Merger with Journey Therapeutics, A Clinical Stage, First-in-Class, Next-Generation ADC-rivalling Nano-immunoconjugates Biopharmaceutical Company

Proposed merger to create Nasdaq-listed, clinical-stage biopharmaceutical company focused on advancing (i) Journey’s next-gen, first-in-class ADC-rivalling, nano-immunoconjugates (“NIC”) platform and therapeutic products for unmet medical needs in oncology and autoimmune diseases and (ii) Entero’s gastrointestinal product pipeline for treating unmet metabolic and rare genetic diseases; The NIC platform technology is invented by and originated from Svetomir N. Markovic, M.D., Ph.D. of Mayo Clinic and is exclusively licensed by Journey with worldwide rights to sublicense; The NIC technology employs the cutting edge cancer drug – nanoparticle albumin-bound (“NAB”) paclitaxel Abraxane – as a therapeutic backbone, combining with (i) on-demand tumor-targeting, tumor-suppressing and/or immune checkpoint inhibitor therapeutic antibody and (ii)...

Continue reading

Teleradiology Market to Surpass USD 30 Billion by 2031 | SkyQuest Technology

Teleradiology Market size is poised to grow from USD 9.58 billion in 2023 to USD 30.13 billion by 2031, growing at a CAGR of 15.40% during the forecast period (2024-2031). Westford, USA, Nov. 13, 2024 (GLOBE NEWSWIRE) — Global Teleradiology Market size to grow from USD 9.58 billion in 2023 to USD 30.13 billion by 2031, growing at a CAGR of 15.40% during the forecast period (2024-2031). In recent times, the Teleradiology Market is witnessing as surge due to the increasing prevalence of target diseases and growing demand for teleradiology to get second opinions during emergencies. Furthermore, the incidence of COVID-19 has also emphasized on the significance of teleradiology. The lack of medialprofessionals, particularly in the sub-specialist segment, like paediatric, neurology, and musculoskeletal radiology are resulting in the...

Continue reading

Cell Line Development Market to Surpass Market Valuation of USD 15.88 Billion by 2031 | SkyQuest Technology

Growing at a CAGR of 9.84% during the forecast period (2024-2031). Westford, USA, Nov. 13, 2024 (GLOBE NEWSWIRE) — SkyQuest projects that the Global Cell Line Development Market will reach a value of USD 15.88 Billion by 2031, with a CAGR of 12.12% during the forecast period (2024-2031). Cell line development, or CLD, will likely become popular as more and more biopharmaceutical companies start sprouting up. Cells are used as an expression host by most biopharma companies to synthesise recombinant monoclonal antibodies and proteins. The market is expected to grow in the upcoming years due to the availability of improved technologies for producing novel cell lines, as well as an increase in demand for cancer medicines and monoclonal antibodies. Download a detailed overview:https://www.skyquestt.com/sample-request/cell-line-development-market Cell...

Continue reading

Mustang Energy Corp. Enters Option Agreement to Acquire Skyharbour’s 914W Uranium Project and Welcomes Jordan Trimble as Strategic Advisor

VANCOUVER, British Columbia, Nov. 13, 2024 (GLOBE NEWSWIRE) — Mustang Energy Corp. (CSE:MEC, OTC:MECPF, FRA:92T) (“Mustang” or the “Company”) is excited to announce that it has entered into a strategic option agreement (the “Agreement”) with Skyharbour Resources Ltd. (TSX-V: SYH) (“Skyharbour”) dated November 12, 2024 to acquire an undivided 75% interest (the “Option”) in Skyharbour’s 914W Uranium Project (the “914W Project”), located in the Athabasca Basin of Northern Saskatchewan. The Option marks an important step for Mustang as it seeks to expand its presence in a promising uranium district. Additionally, Mustang is pleased to welcome Jordan Trimble, President and CEO of Skyharbour, as a Strategic Advisor to the Company, bringing valuable industry insights and expertise to Mustang’s growing portfolio. “Being granted the Option...

Continue reading

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals

Before you continue, please confirm the following:

Professional advisers only

I am a professional adviser and would like to visit the GOLDEA CAPITAL for Professionals website.

Important Notice for Investors:

The services and products offered by Goldalea Capital Ltd. are intended exclusively for professional market participants as defined by applicable laws and regulations. This typically includes institutional investors, qualified investors, and high-net-worth individuals who have sufficient knowledge, experience, resources, and independence to assess the risks of trading on their own.

No Investment Advice:

The information, analyses, and market data provided are for general information purposes only and do not constitute individual investment advice. They should not be construed as a basis for investment decisions and do not take into account the specific investment objectives, financial situation, or individual needs of any recipient.

High Risks:

Trading in financial instruments is associated with significant risks and may result in the complete loss of the invested capital. Goldalea Capital Ltd. accepts no liability for losses incurred as a result of the use of the information provided or the execution of transactions.

Sole Responsibility:

The decision to invest or not to invest is solely the responsibility of the investor. Investors should obtain comprehensive information about the risks involved before making any investment decision and, if necessary, seek independent advice.

No Guarantees:

Goldalea Capital Ltd. makes no warranties or representations as to the accuracy, completeness, or timeliness of the information provided. Markets are subject to constant change, and past performance is not a reliable indicator of future results.

Regional Restrictions:

The services offered by Goldalea Capital Ltd. may not be available to all persons or in all countries. It is the responsibility of the investor to ensure that they are authorized to use the services offered.

Please note: This disclaimer is for general information purposes only and does not replace individual legal or tax advice.